Seahorse Bioscience (Billerica, MA) commercial-stage providers of instruments for cellular bioenergetic measurements for better understanding of the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity, closed a $5M Series D financing. Participants include Commonwealth Capital Ventures, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science [...]

Neomend (Irvine, CA) a commercial-stage developer of sealant and adhesion-prevemtion products focused on the application to visceral pleura for open thoracotomy, closed a $30M Series D financing. Participants include Clarus Ventures, Sanderling Ventures, Novo Ventures, Vivo Ventures and Prospect Venture Partners.

EyeGate Pharma (Wlatham, MA) a clinical-stage company focused on a non-invasive iontophoresis drug delivery system for ocular therapeutics, closed a $22.6M Series D financing. Participants include Natixis Private Equity, Emerging Capital, Ventech, Innoven Partners and Medicis Capital.

Intuity Medical (Sunnyvale, CA) a clinical-stage diagnostic device company focused on all-in-one blood sample collection and glucose analysis, closed a Series D financing. Participants include Venrock, Emergent Medical Partners, Investor Growth Capital, Thomas McNerney and Partners, U.S. Venture Partners and Versant Ventures.

ReVance Therapeutics (Mountain View, CA) a clinical-stage biopharmaceutical company focused on dermatology and aesthetic medicine, closed a $25.6M Series D financing. Particpants have included Essex Woodlands Health Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Bio*One Capital and Pac-Link Venture.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Tethys Bioscience (Emeryville, CA) a commercial-stage diagnostics company focused on type II diabetes risk assessment through the measurement of multiple biomarkers, closed a $25M Series D financing. Participants include Capital AG, Wasatch Advisors, Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Entellus Medical (Maple Grove, MN) a commercial-stage medical device company focused on the treatment for chronic sinusitis, closed a $30M Series D financing. Participants include Essex Woodlands Health Ventures, Split Rock Partners and SV Life Sciences.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Adimab (Lebanon, NH) a commercial-stage yeast-based antibody discovery and optimization platform, closed a $8.2M Series D financing. Participants include Google Ventures, OrbiMed, Borealis Ventures,Polaris Venture Partners and SV Life Sciences.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Vertos Medical (Aliso Viejo, CA) a commercial stage medical device company focused on providing minimally invasive alternatives for surgical procedures to treat lumbar spinal stenosis, closed a $15.5M Series D financing. Participants include Onset Ventures, CHL Medical Partners, Foundation Medical Partners, Aweida Venture Partners and DFJ Mercury.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.